Loncar Cancer Price To Earning vs. Price To Book
| CNCR Etf | USD 13.74 0.45 3.17% |
For Loncar Cancer profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Loncar Cancer to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Loncar Cancer Immunotherapy utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Loncar Cancer's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Loncar Cancer Immunotherapy over time as well as its relative position and ranking within its peers.
Loncar |
The market value of Loncar Cancer Immuno is measured differently than its book value, which is the value of Loncar that is recorded on the company's balance sheet. Investors also form their own opinion of Loncar Cancer's value that differs from its market value or its book value, called intrinsic value, which is Loncar Cancer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Loncar Cancer's market value can be influenced by many factors that don't directly affect Loncar Cancer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Loncar Cancer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Loncar Cancer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Loncar Cancer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Loncar Cancer Immuno Price To Book vs. Price To Earning Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Loncar Cancer's current stock value. Our valuation model uses many indicators to compare Loncar Cancer value to that of its competitors to determine the firm's financial worth. Loncar Cancer Immunotherapy is second largest ETF in price to earning as compared to similar ETFs. It is the top ETF in price to book as compared to similar ETFs fabricating about 0.08 of Price To Book per Price To Earning. The ratio of Price To Earning to Price To Book for Loncar Cancer Immunotherapy is roughly 12.38 . Comparative valuation analysis is a catch-all technique that is used if you cannot value Loncar Cancer by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Loncar Price To Book vs. Price To Earning
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Loncar Cancer |
| = | 24.63 X |
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Loncar Cancer |
| = | 1.99 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Loncar Price To Book Comparison
Loncar Cancer is currently under evaluation in price to book as compared to similar ETFs.
Loncar Cancer Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Loncar Cancer, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Loncar Cancer will eventually generate negative long term returns. The profitability progress is the general direction of Loncar Cancer's change in net profit over the period of time. It can combine multiple indicators of Loncar Cancer, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the funds index provider, as having a high strategic focus on the development of drugs that harness the bodys own immune system to fight cancer. Loncar Cancer is traded on NASDAQ Exchange in the United States.
Loncar Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Loncar Cancer. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Loncar Cancer position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Loncar Cancer's important profitability drivers and their relationship over time.
Use Loncar Cancer in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Loncar Cancer position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Loncar Cancer will appreciate offsetting losses from the drop in the long position's value.Loncar Cancer Pair Trading
Loncar Cancer Immunotherapy Pair Trading Analysis
The ability to find closely correlated positions to Loncar Cancer could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Loncar Cancer when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Loncar Cancer - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Loncar Cancer Immunotherapy to buy it.
The correlation of Loncar Cancer is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Loncar Cancer moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Loncar Cancer Immuno moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Loncar Cancer can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Loncar Cancer position
In addition to having Loncar Cancer in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Large Blend Funds Thematic Idea Now
Large Blend Funds
Fund or Etfs that invest in stocks of large organizations that have characteristics of both growth and value companies. The Large Blend Funds theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large Blend Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
To fully project Loncar Cancer's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Loncar Cancer Immuno at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Loncar Cancer's income statement, its balance sheet, and the statement of cash flows.